CN102266524B - Traditional Chinese medicine for treating chronic heart failure and preparation method thereof - Google Patents
Traditional Chinese medicine for treating chronic heart failure and preparation method thereof Download PDFInfo
- Publication number
- CN102266524B CN102266524B CN2011101905271A CN201110190527A CN102266524B CN 102266524 B CN102266524 B CN 102266524B CN 2011101905271 A CN2011101905271 A CN 2011101905271A CN 201110190527 A CN201110190527 A CN 201110190527A CN 102266524 B CN102266524 B CN 102266524B
- Authority
- CN
- China
- Prior art keywords
- weight portions
- heart failure
- chinese medicine
- chronic heart
- treating chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine for treating chronic heart failure and a preparation method thereof. The traditional Chinese medicine for treating chronic heart failure is prepared from the following active pharmaceutical ingredients in parts by weight: 10-14 parts of ginseng, 40-50 parts of radix astragali, 10-14 parts of kudzu root, 13-17 parts of hemlock parsley, 8-12 parts of Eupolyphaga, 8-12 parts of pollen typhae, 13-17 parts of motherwort, 8-12 parts of trichosanthes kirilowii Maxim and 13-17 parts of amomum fruit. The preparation method comprises the following steps: pulverizing the active pharmaceutical ingredients, evenly mixing, decorating while adding water three times, filtering, and merging the filtrates to obtain the traditional Chinese medicine for treating chronic heart failure. The traditional Chinese medicine for treating chronic heart failure can inhibit reconstruction of cardiac muscles, enhance exercise tolerance of patients, improve contraction function, improve the heart failure symptoms as quickly as possible, improve heart failure prognosis, enhance the quality of life, replenish qi to invigorate the spleen, resolve phlegm, eliminate blood stasis, obviously regulate the incretion activity of nerves and improve the contraction function of the left ventricle, and does not have obvious toxic or side effect.
Description
Technical field
The present invention relates to technical field of Chinese medicines, relate in particular to a kind of Chinese medicine of treating chronic heart failure and preparation method thereof.
Background technology
Heart failure is the end stage eventually of various cardiovascular disease, and various internal and external factors are if load is overweight for a long time before and after causing heart, and cardiomyopathy undermines contractility to be weakened, and all can cause the generation of heart failure.Along with medical development, heart failure is treated also in continuous progress.Along with deepening continuously of heart failure research and understanding.Nearly ten years; Basic change has appearred in the Pathologic and Physiological Function of Heart Failure notion; It is found that, the behind that chronic heart failure symptom and hemodynamics worsen, it is disorderly to exist serious neuro-endocrinology hormone; Be the excessive activation of sympathetic nerve epinephrine system and feritin-RAAS (RAAS), and their activation degree and long-term prognosis are varied to positive correlation; Immune movable unusual during heart failure, panimmunity mechanism is participated in the pathophysiological process of heart failure.It is reported that nineteen ninety Magnasson etc. at first finds in DCM patient's serum, to exist the autoantibody of heart β1Shen Shangxiansunengshouti; Positive rate is 40%～50% [3] in the patients with heart failure serum of the various causes of disease.Fn in 1993 etc. find also to exist in this patient's serum the autoantibody of anti-M2 acetylcholinergic receptor again.Domestic scholars Zhang Lin etc. detect β 1 and M2 receptor again in the patients with heart failure serum due to the various heart diseases (ischemic heart desease, dilated cardiomyopathy, hypertensive heart disease) autoantibody positive rate and antibody titer all significantly increase, with the sick noncausal relationship of primary cardiac.The autoantibody of animal experiment prompting β1Shen Shangxiansunengshouti has the agonist-like effect to receptor; Cause the sympathetic nerve excessive activation; Act on β1Shou Ti constantly and raise, and the pathological change (comprising that ventricle wall attenuation, the ventricular dilatation of carrying out property and cardiac function descend) of similar dilated cardiomyopathy occurs.At the ischemic heart desease autoantibody receptor is produced same agonist-like effect equally, and difficult desensitization, long-term chronic stimulation causes myocardial damage, participates in the pathology generating process that heart failure takes place, develops, thereby quickens the process that heart failure worsens.Research at present thinks that this effect can be blocked by β1Shou Tizuzhiji.
Clinical center force failure witness is complicated, and existing dyspnea with rapid and short breath has cough again, coughs up phlegm, has palpitation, uncomfortable in chest, edema, indigestion and loss of appetite, abdominal distention, oliguria, can not equal various clinical symptoms such as for sleeping in.So professor Deng Tietao thinks that in the generation of heart failure, the heart, lung, spleen, kidney, liver the five internal organs are all got involved deficient and excessive syndromes appearing together.In the five internal organs, heart spleen is a mother child relation, so in the pathology of heart failure developed, the relation of the spleen and the heart was the closest, because of the spleen being the foundation of acquired constitution, main fortuneization, ascending the clear and descending the turbid are the hinge of the whole body mechanism of qi, and the prosperous then four visceral-qi machines of spleen are sensible, and QI and blood is in harmonious proportion.On the contrary, the function mistake department of spleen, then whole body QI-blood circulation is not smooth, and is biochemical passive, must bring out and increase the weight of the generation of heart failure.Yet in this many pathogenesis factor, sick position be the heart at all, at all being of deficiency and excess " void " distinguished when controlling heart failure, stresses that the five internal organs are relevant, is this with the heart, deficiency in origin and excess in superficiality, " focusing on tonify deficiency ".In the morbidity of heart failure, " expectorant " and " stasis of blood " is important pathological factor wherein, both has been the pathological product of heart, spleen and kidney functions imbalance, and becoming conversely again influences the pathology of the function factor.Expectorant and the stasis of blood, closely related, be easy to mutual biography, the abundant expectoration stasis of blood of holding concurrently, the stasis of blood expectorant of holding concurrently more.The academic thought relevant according to the five internal organs, that the expectorant stasis of blood is relevant, the five internal organs are an integral body, control taste and can pacify four dirtyly, transfer four dirtyly can also pacify taste.So the treatment heart failure is worked as treating both the principal and secondary aspects of a disease, is method with replenishing QI to invigorate the spleen, the clots absorbing that reduces phlegm.
Summary of the invention
Technical problem to be solved by this invention provides the Chinese medicine of the treatment chronic heart failure of the side effect of a kind of effective control western medical treatment, no obvious toxic-side effects.
For solving the problems of the technologies described above, technical scheme of the present invention is: a kind of Chinese medicine of treating chronic heart failure, process by following bulk drugs:
Radix Ginseng 10～14 weight portions, the Radix Astragali 40～50 weight portions, Radix Puerariae 10～14 weight portions, Rhizoma Chuanxiong 13～17 weight portions, eupolyphaga 8～12 weight portions, Pollen Typhae 8～12 weight portions, Herba Leonuri 13～17 weight portions, Fructus Trichosanthis 8～12 weight portions, Fructus Amomi 13～17 weight portions.
As optimized technical scheme, described a kind of Chinese medicine of treating chronic heart failure, process by following bulk drugs:
Radix Ginseng 12 weight portions, the Radix Astragali 45 weight portions, Radix Puerariae 12 weight portions, Rhizoma Chuanxiong 15 weight portions, eupolyphaga 10 weight portions, Pollen Typhae 10 weight portions, Herba Leonuri 15 weight portions, Fructus Trichosanthis 10 weight portions, Fructus Amomi 15 weight portions.
Wherein: Radix Ginseng, the Radix Astragali are monarch drug altogether, the ability spleen reinforcing benefit heart, strongly invigorating primordial QI; The ability blood vessel dilating, it is capable to improve blood, the endocrine regulation system activity; Reduce regional myocardial RA, AngII activity, its effect is because regional myocardial RA, AngII endocrine and paracrine are had obvious inhibitory action, has and boosts; Heart tonifying and improve the peripheral circulation effect can make cardiac contractile force strengthen and the coronary artery circulation improvement; The Radix Astragali can also be subsided a swelling in QI invigorating; Radix Puerariae has the expansion cardiovascular and cerebrovascular vessel to improve the heart and brain Circulation, and similar beta-blocker appearance effect is arranged, and can play the inhibition myocardial remodelling, improve heart failure patient's cardiac function, and the ability promoting the production of body fluid to quench thirst; The Rhizoma Chuanxiong blood-activating and qi-promoting can directly be expanded peripheral vessels, and coronary artery blood flow and lower extremity blood flow amount are increased, and improves cardiac function; Radix Puerariae, Rhizoma Chuanxiong are ministerial drug altogether.Assistant has anticoagulation and blood vessel dilating with eupolyphaga, Pollen Typhae, Herba Leonuri removing blood stasis, and blood circulation promoting reduces myocardial oxygen consumption, the effect of protection vascular endothelial function; Water in the Herba Leonuri blood has diuresis, reduces the effect of cardiac preload; Make it the Fructus Trichosanthis relieving stuffiness of the chest by dispersing aggregation of pathogens that reduces phlegm, expansion heart arteria coronaria increases the coronary flow effect, and acute myocardial ischemia is had the significant protection effect, improves myocardial hypoxia tolerance.Make it Fructus Amomi removing dampness appetizing, warming spleen and stopping diarrha, anticoagulant is promoted intestinal movement, and the abdominal distension and anorexia of heart failure and nausea and vomiting etc. are had good effect.
Another technical problem to be solved by this invention provides a kind of method for preparing the Chinese medicine of chronic heart failure.
For solving the problems of the technologies described above, technical scheme of the present invention is: a kind of method for preparing the Chinese medicine of chronic heart failure: get Radix Ginseng 10～14 weight portions, the Radix Astragali 40～50 weight portions, Radix Puerariae 10～14 weight portions, Rhizoma Chuanxiong 13～17 weight portions, eupolyphaga 8～12 weight portions, Pollen Typhae 8～12 weight portions, Herba Leonuri 13～17 weight portions, Fructus Trichosanthis 8～12 weight portions, Fructus Amomi 13～17 weight portions, pulverize and mixing; Adding weight is the water of 11～13 times of said crude drug gross weights, under 95～105 ℃, decocts 55～65 minutes; Leach medicinal liquid, in medicinal residues, adding weight then is the water of 9～11 times of said crude drug gross weights, under 95～105 ℃; Decocted 55～65 minutes; Leach medicinal liquid, in medicinal residues, adding weight afterwards is the water of 7～9 times of said crude drug gross weights, under 95～105 ℃; Decocted 55～65 minutes; Leach medicinal liquid,, promptly get the Chinese medicine of said treatment chronic heart failure the combining medicine that leaches for three times.
As optimized technical scheme, weight portion preferably ginseng 12 weight portions of said crude drug, the Radix Astragali 45 weight portions, Radix Puerariae 12 weight portions, Rhizoma Chuanxiong 15 weight portions, eupolyphaga 10 weight portions, Pollen Typhae 10 weight portions, Herba Leonuri 15 weight portions, Fructus Trichosanthis 10 weight portions, Fructus Amomi 15 weight portions.
As improvement to above-mentioned technology, the Chinese medicine of said treatment chronic heart failure concentrated obtain clear paste, the dextrin that said clear paste and premix is good and the mixture mixing of sucrose are processed medicated powder, with said medicated powder drying in being lower than 80 ℃ environment.
As optimized technical scheme, the density with respect to water of said clear paste is 1.25～1.35.
As optimized technical scheme, the dextrin that said clear paste and premix are good and the mixture of sucrose mix by 1: 1 weight ratio.
As optimized technical scheme, said dextrin and sucrose are pressed 4: 1 weight ratio mixing.
As improvement to above-mentioned technology, with said medicated powder process granule incapsulate, screen, clean dry, packing, promptly get the Chinese medicinal capsule preparation of said chronic heart failure.
As another modification of the above techniques can also be particles of the powder into tablets or granules La.
The Chinese medicinal capsule preparation usage and the consumption of chronic heart failure: oral, each 3-4 grain, every day 3 times; Every dress of the Chinese medicinal capsule preparation of said chronic heart failure 0.4g.
Contraindication: hemorrhagic illness, anemia of pregnant woman and gynecologic menstrual forbidding, the careful usefulness of hyperactivity of fire caused by deficiency of YIN person; Avoid pungently, raw and cold, greasy, the back stomach discomfort person that takes medicine should change one after each meal into.
Owing to adopted technique scheme; A kind of Chinese medicine of treating chronic heart failure and preparation method thereof is processed by following bulk drugs: Radix Ginseng 10～14 weight portions, the Radix Astragali 40～50 weight portions, Radix Puerariae 10～14 weight portions, Rhizoma Chuanxiong 13～17 weight portions, eupolyphaga 8～12 weight portions, Pollen Typhae 8～12 weight portions, Herba Leonuri 13～17 weight portions, Fructus Trichosanthis 8～12 weight portions, Fructus Amomi 13～17 weight portions; Said crude drug is pulverized and mixing, added water and decoct after-filtration for three times and merge the Chinese medicine that obtains said treatment chronic heart failure, can suppress myocardial remodelling, improve the patient moving tolerance; Improve contractile function, on the basis of Western medicine, add the effect of playing the curative effect addition with Chinese herbal medicine, effectively prevent and treat the western medical treatment side effect; Can improve symptoms of heart failure as early as possible, improve the heart failure prognosis, improve the quality of living, replenishing QI to invigorate the spleen, the clots absorbing that reduces phlegm, no obvious toxic-side effects; Can obviously regulate the neuroendocrine activity, suppress myocardial remodelling, improve left chamber contractile function; Potential applicability in clinical practice is wide, and method is simple, is worthy to be popularized.
In order to further specify the present invention, the Chinese medicinal capsule preparation of the chronic heart failure that makes has been carried out clinical research:
(1), object of study
1. case is selected: 80 routine patients with heart failure are that year January in January, 2007 to 2009 is at my section's inpatient.Male's 45 examples wherein, women's 35 examples, year at age 44～76 (61.72 ± 5.68).Wherein: DCM 25 examples, ischemic heart desease 30 examples, hypertensive cardiopathy 25 examples.Heart failure medical history 4 months～10 years, average 3.1 years.All case is all through echocardiography, and the contrast examination of ischemic heart desease underwent coronary is clear and definite.Adopt ELISA to measure serum beta 1 receptor autophosphorylation antibody horizontal, be divided into the positive group of β1Shou Ti autoantibody (β 1 positive group) 40 examples in view of the above, male 25 people wherein, women 15 people; With the negative group of β1Shou Ti autoantibody (β 1 negative group) 40 examples, male 20 people wherein, women 20 people.Be divided into SHENQI JIAONANG treatment group and conventional heart failure treatment matched group at random in β 1 positive group then; β 1 negative group is divided into SHENQI JIAONANG treatment group and conventional heart failure treatment matched group at random.Matched group is conventional heart failure treatment such as angiotensin-convertion enzyme inhibitor, beta receptor blocker, diuretic, digitalis preparation.SHENQI JIAONANG treatment group is to add with Chinese medicine SHENQI JIAONANG (each 3～4,0.4g/ grain, every day three times) on the conventional heart failure treatment application foundation.Each organizes clinical setting: two groups at each side not statistically significants such as age, sex, medical history, cardiac functional grading, Type B urine sodium peptide, Drug therapys.
2. inclusion criteria: at 44～76 years old age, New York cardiac functional grading (NYHAA) II-IV level, heart failure medical history at least＞4 month are not previously used Chinese herbal and crude drugs preparations.
3. exclusion standard: above atrioventricular block person (2) the permanent pacemaker person of inserting (3) severe hepatic of (1) two degree, (4) serious digestive tract illness of renal dysfunction can not be obeyed Chinese herbal medicine (5) gestation and nursing women.
(2), research method
1.NYHA cardiac functional grading method: all 80 routine patients are carried out the NYHA cardiac functional grading when selected and treatment finished in 6 months, the variation of symptom before and after the treatment of evaluation heart failure.
2.6 minute gait test: the chronic heart failure patient carries out gait test in 6 minutes when selected and treatment finished in 6 months, carry out the assessment of cardiac function.
3. adopt Doppler's 2-dimensional echocardiography (2DE): all 80 routine patients are carried out left chamber major axis, minor axis and apex of the heart tangent plane LDF inspection and keep image when selected and treatment finished in 6 months, the analysis foundation is provided.
4. cardiac determination: adopt the HP2500 ultrasound cardiograph before and after treatment, to measure diastole end, left chamber diameter (LVEDD), footpath, end (LVESD) is shunk in left chamber, LVEDV (LVEDV), and last volume (LVESV) and left ventricular ejection mark (LVEF) are shunk in left chamber.
5. lab testing: venous blood samples when 80 routine patients finished in selected and treatment in 6 months, use and put the method for exempting from and measure the short natruresis peptide (BNP) of Type B, β1Shou Ti autoantibody, c reactive protein (CRP) level in patient's blood respectively.
6. statistical method: measurement data representes that with mean ± standard deviation two groups of means are relatively with the t check, and mean is handled and on the SPSS12.0 statistical package, carried out, and is that difference has statistical significance with P＜0.05.
Two, result
1. two groups general clinical data and medicining condition: two groups of patient ages, sickly plant, the heart failure diseases all mate (P＞0.05).Take medicine and Chinese medicine formula not statistically significant (P＞0.05) for two groups.
2. carry out the NYHA cardiac functional grading after two groups of treatments, all obviously raise, treat front and back relatively, P＜0.01 than rank before the treatment.
3. treat front and back heart rate, blood pressure situation (table 1) for two groups: the β 1 positive heart rate of organizing is significantly higher than β 1 feminine gender group (P＜0.05) before the treatment.The two groups of hearts rate in treatment back, blood pressure are all than significantly lowering (P＜0.01) before the treatment, β 1 positive group heart rate and β 1 negative group difference not statistically significant (P＞0.05).SHENQI JIAONANG treatment group in each group compares with matched group, there was no significant differences before two groups of treatments, and P＜0.01 is compared in the treatment back.
The comparison
of heart rate, blood pressure before and after the table 1 liang group treatment
Annotate: before the treatment, β 1 positive group compares with β 1 negative group, two groups of △ P＜0.05, treatment back and the two groups of preceding relatively △ △ of treatment P＜0.01.SHENQI JIAONANG treatment group in each group compares with matched group, there was no significant differences before two groups of treatments, treatment back ※ P＜0.01.
4. two groups of treatment front and back ultrasonic cardiography graph parameters compare (table 2): before the treatment, significantly greater than β 1 negative organize (P＜0.05), LVESD is greater than β 1 feminine gender group (P=0.052) for β 1 positive group LVEDD, and LVEF significantly is lower than β 1 negative group (P＜0.05).After the treatment, all than significantly reducing (P＜0.01) before the treatment, LVEF improves (P＜0.01) before the treatment for two groups of LVEDD, LVESD.β 1 positive group LVEDD, LVESD and LVEF and β 1 negative group difference not statistically significant (P＞0.05).SHENQI JIAONANG treatment group in each group, with matched group relatively, there was no significant differences before two groups of treatments, LVEDD, LVESD all significantly reduce before the treatment before treatment back and the two groups of treatments, LVEF is raising P＜0.05 before the treatment.
The comparison of ultrasonic cardiography graph parameter before and after the table 2 liang group treatment (± s)
Annotate: compare △ P＜0.05 with β 1 feminine gender group, compare △ △ P＜0.01 before treating with two groups.SHENQI JIAONANG treatment group in each group compares with matched group, there was no significant differences before two groups of treatments, and ※ P＜0.05 is compared in the treatment back.
5. two groups of treatment front and back Type B urine sodium peptides (BNP) contrast: before the treatment, β 1 positive group BNP is apparently higher than β 1 feminine gender group, (P＜0.05); Two groups of treatment back BNP significantly reduce (P＜0.05) before the treatment.
6. two groups of variations (table 3) of treating anti-heart β1Shou Ti autoantibody titre in the serum of front and back: before the treatment, β 1 positive group serum anti heart β1Shou Ti autoantibody titre is organized (P＜0.01) apparently higher than β 1 feminine gender; Two groups of treatment back serum anti heart β1Shou Ti autoantibody titres significantly reduce (P＜0.01) before the treatment.SHENQI JIAONANG treatment group in each group compares with matched group, there was no significant differences before two groups of treatments, and P＜0.05 is compared in the treatment back.
Anti-heart β1Shou Ti autoantibody titre comparison in the serum before and after the table 3 liang group treatment (± s)
Notes: before the treatment and β 1 negative relatively △ P＜0.01 of organizing, with the two groups of preceding relatively △ △ of treatment P＜0.01.SHENQI JIAONANG treatment group in each group compares with matched group, there was no significant differences before two groups of treatments, and ※ P＜0.05 is compared in the treatment back.
7. the 6 minutes gait test results' in two groups of treatment front and back variation (table 4): β 1 positive group shortens (P＜0.05) than 6 minutes walking distances of β 1 feminine gender group before the treatment.The preceding 6 minutes equal significant prolongations of walking distance (P＜0.01) are treated for two groups in the treatment back, 6 minutes gait test result difference not statistically significants (P＞0.05) of treatment back β 1 positive group and β 1 negative group.SHENQI JIAONANG treatment group in each group compares with matched group, there was no significant differences before two groups of treatments, and P＜0.05 is compared in the treatment back.
Gait test result comparison in 6 minutes before and after the table 4 liang group treatment (± s)
Annotate: compare △ P＜0.05 with β 1 negative group before treating, treatment back and the two groups of preceding relatively △ △ of treatment P＜0.01.SHENQI JIAONANG treatment group in each group compares with matched group, there was no significant differences before two groups of treatments, and ※ P＜0.05 is compared in the treatment back.
The specific embodiment
Below in conjunction with embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in the restriction scope of the present invention.Should be understood that in addition those skilled in the art can do various changes or modification to the present invention after the content of having read the present invention's instruction, these equivalent form of values fall within the application's appended claims institute restricted portion equally.
Embodiment one:
Get Radix Ginseng 10g, Radix Astragali 40g, Radix Puerariae 10g, Rhizoma Chuanxiong 13g, eupolyphaga g, Pollen Typhae 8g, Herba Leonuri 13g, Fructus Trichosanthis 8g, Fructus Amomi 13g, pulverize and mixing, adding weight is the water of 11 times of said crude drug gross weights, under 95 ℃; Decocted 65 minutes, and leached medicinal liquid, in medicinal residues, adding weight then is the water of 9 times of said crude drug gross weights; Under 95 ℃, decocted 65 minutes, leach medicinal liquid; In medicinal residues, adding weight afterwards is the water of 7 times of said crude drug gross weights, under 95 ℃, decocts 65 minutes; Leach medicinal liquid,, promptly get the Chinese medicine of said treatment chronic heart failure the combining medicine that leaches for three times.
The Chinese medicine of said treatment chronic heart failure concentrated obtain clear paste, the dextrin that said clear paste and premix is good and the mixture mixing of sucrose are processed medicated powder, with said medicated powder drying in being lower than 80 ℃ environment.
The density with respect to water of said clear paste is 1.25.
The dextrin that said clear paste and premix are good and the mixture of sucrose mix by 1: 1 weight ratio.
Said dextrin and sucrose are pressed 4: 1 weight ratio mixing.
With said medicated powder process granule incapsulate, screen, clean dry, packing, promptly get the Chinese medicinal capsule preparation of said chronic heart failure.
Embodiment two:
Get Radix Ginseng 12g, Radix Astragali 45g, Radix Puerariae 12g, Rhizoma Chuanxiong 15g, eupolyphaga 10g, Pollen Typhae 10g, Herba Leonuri 15g, Fructus Trichosanthis 10g, Fructus Amomi 15g, pulverize and mixing, adding weight is the water of 12 times of said crude drug gross weights, under 100 ℃; Decocted 60 minutes, and leached medicinal liquid, in medicinal residues, adding weight then is the water of 10 times of said crude drug gross weights; Under 100 ℃, decocted 60 minutes, leach medicinal liquid; In medicinal residues, adding weight afterwards is the water of 8 times of said crude drug gross weights, under 100 ℃, decocts 60 minutes; Leach medicinal liquid,, promptly get the Chinese medicine of said treatment chronic heart failure the combining medicine that leaches for three times.
The Chinese medicine of said treatment chronic heart failure concentrated obtain clear paste, the dextrin that said clear paste and premix is good and the mixture mixing of sucrose are processed medicated powder, with said medicated powder drying in being lower than 80 ℃ environment.
The density with respect to water of said clear paste is 1.30.
The dextrin that said clear paste and premix are good and the mixture of sucrose mix by 1: 1 weight ratio.
Said dextrin and sucrose are pressed 4: 1 weight ratio mixing.
With said medicated powder process granule incapsulate, screen, clean dry, packing, promptly get the Chinese medicinal capsule preparation of said chronic heart failure.
Embodiment three:
Get Radix Ginseng 14g, Radix Astragali 50g, Radix Puerariae 14g, Rhizoma Chuanxiong 17g, eupolyphaga 12g, Pollen Typhae 12g, Herba Leonuri 17g, Fructus Trichosanthis 12g, Fructus Amomi 17g, pulverize and mixing, adding weight is the water of 13 times of said crude drug gross weights, under 105 ℃; Decocted 65 minutes, and leached medicinal liquid, in medicinal residues, adding weight then is the water of 11 times of said crude drug gross weights; Under 105 ℃, decocted 65 minutes, leach medicinal liquid; In medicinal residues, adding weight afterwards is the water of 9 times of said crude drug gross weights, under 105 ℃, decocts 65 minutes; Leach medicinal liquid,, promptly get the Chinese medicine of said treatment chronic heart failure the combining medicine that leaches for three times.
The Chinese medicine of said treatment chronic heart failure concentrated obtain clear paste, the dextrin that said clear paste and premix is good and the mixture mixing of sucrose are processed medicated powder, with said medicated powder drying in being lower than 80 ℃ environment.
The density with respect to water of said clear paste is 1.35.
The dextrin that said clear paste and premix are good and the mixture of sucrose mix by 1: 1 weight ratio.
As optimized technical scheme, said dextrin and sucrose are pressed 4: 1 weight ratio mixing.
With said medicated powder process granule incapsulate, screen, clean dry, packing, promptly get the Chinese medicinal capsule preparation of said chronic heart failure.
More than show and described ultimate principle of the present invention, principal character and advantage of the present invention.The technical staff of the industry should understand; The present invention is not restricted to the described embodiments; That describes in the foregoing description and the description just explains principle of the present invention; Under the prerequisite that does not break away from spirit and scope of the invention, the present invention also has various changes and modifications, and these variations and improvement all fall in the scope of the invention that requires protection.The present invention requires protection domain to be defined by appending claims and equivalent thereof.
Claims (9)
1. a Chinese medicine of treating chronic heart failure is characterized in that, is processed by following bulk drugs:
Radix Ginseng 10～14 weight portions, the Radix Astragali 40～50 weight portions, Radix Puerariae 10～14 weight portions, Rhizoma Chuanxiong 13～17 weight portions, eupolyphaga 8～12 weight portions, Pollen Typhae 8～12 weight portions, Herba Leonuri 13～17 weight portions, Fructus Trichosanthis 8～12 weight portions, Fructus Amomi 13～17 weight portions.
2. a kind of Chinese medicine of treating chronic heart failure as claimed in claim 1 is characterized in that, is processed by following bulk drugs:
Radix Ginseng 12 weight portions, the Radix Astragali 45 weight portions, Radix Puerariae 12 weight portions, Rhizoma Chuanxiong 15 weight portions, eupolyphaga 10 weight portions, Pollen Typhae 10 weight portions, Herba Leonuri 15 weight portions, Fructus Trichosanthis 10 weight portions, Fructus Amomi 15 weight portions.
3. a method for preparing the Chinese medicine of treatment chronic heart failure as claimed in claim 1 is characterized in that: get Radix Ginseng 10～14 weight portions, the Radix Astragali 40～50 weight portions, Radix Puerariae 10～14 weight portions, Rhizoma Chuanxiong 13～17 weight portions, eupolyphaga 8～12 weight portions, Pollen Typhae 8～12 weight portions, Herba Leonuri 13～17 weight portions, Fructus Trichosanthis 8～12 weight portions, Fructus Amomi 13～17 weight portions, pulverize and mixing; Adding weight is the water of 11～13 times of said crude drug gross weights, under 95～105 ℃, decocts 55～65 minutes; Leach medicinal liquid, in medicinal residues, adding weight then is the water of 9～11 times of said crude drug gross weights, under 95～105 ℃; Decocted 55～65 minutes; Leach medicinal liquid, in medicinal residues, adding weight afterwards is the water of 7～9 times of said crude drug gross weights, under 95～105 ℃; Decocted 55～65 minutes; Leach medicinal liquid,, promptly get the Chinese medicine of said treatment chronic heart failure the combining medicine that leaches for three times.
4. a kind of method for preparing the Chinese medicine of treating chronic heart failure as claimed in claim 3 is characterized in that: weight portion preferably ginseng 12 weight portions of said crude drug, the Radix Astragali 45 weight portions, Radix Puerariae 12 weight portions, Rhizoma Chuanxiong 15 weight portions, eupolyphaga 10 weight portions, Pollen Typhae 10 weight portions, Herba Leonuri 15 weight portions, Fructus Trichosanthis 10 weight portions, Fructus Amomi 15 weight portions.
5. a kind of method for preparing the Chinese medicine of treating chronic heart failure as claimed in claim 3; It is characterized in that: with the concentrated clear paste that obtains of the Chinese medicine of said treatment chronic heart failure; The dextrin that said clear paste and premix is good and the mixture mixing of sucrose are processed medicated powder, and said medicated powder is dry in being lower than 80 ℃ environment.
6. a kind of method for preparing the Chinese medicine of treating chronic heart failure as claimed in claim 5 is characterized in that: the density with respect to water of said clear paste is 1.25～1.35.
7. a kind of method for preparing the Chinese medicine of treating chronic heart failure as claimed in claim 6 is characterized in that: the dextrin that said clear paste and premix are good and the mixture of sucrose mix by 1: 1 weight ratio.
8. a kind of method for preparing the Chinese medicine of treating chronic heart failure as claimed in claim 7 is characterized in that: said dextrin and sucrose are pressed 4: 1 weight ratio mixing.
9. a kind of method for preparing the Chinese medicine of treating chronic heart failure as claimed in claim 6 is characterized in that: with said medicated powder process granule incapsulate, screen, clean dry, packing, promptly get the Chinese medicinal capsule preparation of said treatment chronic heart failure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101905271A CN102266524B (en) | 2011-07-08 | 2011-07-08 | Traditional Chinese medicine for treating chronic heart failure and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101905271A CN102266524B (en) | 2011-07-08 | 2011-07-08 | Traditional Chinese medicine for treating chronic heart failure and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102266524A CN102266524A (en) | 2011-12-07 |
| CN102266524B true CN102266524B (en) | 2012-08-08 |
Family
ID=45049104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101905271A Expired - Fee Related CN102266524B (en) | 2011-07-08 | 2011-07-08 | Traditional Chinese medicine for treating chronic heart failure and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102266524B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632758A (en) * | 2008-07-24 | 2010-01-27 | 夏范音 | Chinese medicinal composition for invigorating qi and promoting blood circulation, and removing obstruction in channels to relieve pain |
-
2011
- 2011-07-08 CN CN2011101905271A patent/CN102266524B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632758A (en) * | 2008-07-24 | 2010-01-27 | 夏范音 | Chinese medicinal composition for invigorating qi and promoting blood circulation, and removing obstruction in channels to relieve pain |
Non-Patent Citations (2)
| Title |
|---|
| 张艳等.慢性心衰中医病机及临床辨证治疗体会.《中华中医药学会心病分会全国第十二次学术年会暨中华中医药学会心病分会换届选举工作会议论文精选》.2010,第276-281页. * |
| 杨维华等.丹芎通络汤治疗高血压性心脏病并左室舒张功能不全的临床观察.《中国中西医结合杂志》.2002,第22卷(第11期),第819-821页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102266524A (en) | 2011-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101780254B (en) | Traditional Chinese medicine compound for treating intestinal tumor | |
| CN108743892A (en) | The preparation method and applications of " Shengyang Yiwei Decoction " side's Chinese medical extract | |
| CN101670056B (en) | Medicament for treating malignant tumor | |
| CN101085200A (en) | Traditional Chinese medicine composition for treating heart failure and preparation method thereof | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN104825788A (en) | Application of traditional Chinese medicine composition in preparation of drug for treating transient ischemic attack | |
| CN101695546B (en) | Chinese medicament for treating alimentary tract cancer and preparation method thereof | |
| CN103977362A (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands and early-stage breast cancer | |
| CN111686185A (en) | Traditional Chinese medicine composition for treating dilated cardiomyopathy and preparation method thereof | |
| CN108379420B (en) | Traditional Chinese medicine composition for treating heart failure and edema and application thereof | |
| CN104208303B (en) | A kind of Chinese medicine preparation for treating hyperlipemia and preparation method thereof | |
| CN103316144B (en) | Chinese medicine composition capable of invigorating qi and blood, nourishing yin and yang, improving immunity, resisting to fatigue and inhibiting thrombogenesis | |
| CN109498731A (en) | A kind of tonifying speen and tonifying kidney tune sugar-pill and preparation method thereof for treating diabetes B Pishenqixu syndrome | |
| CN102266524B (en) | Traditional Chinese medicine for treating chronic heart failure and preparation method thereof | |
| CN106421559A (en) | Traditional Chinese medicine preparation for curing hyperuricemia and preparation method thereof | |
| CN104998087A (en) | Traditional Chinese medicine composition for treating primary hypertension and preparing method of traditional Chinese medicine composition | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN104984097A (en) | Chinese herba preparation for treating primary hypertension and application thereof | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN102327435A (en) | Traditional Chinese herb preparation for treating gout | |
| CN102406770A (en) | Shenkangding Jiaonang for treating chronic nephrosis | |
| CN108524762B (en) | Pharmaceutical composition for treating chronic heart failure and application thereof | |
| CN101618187A (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN105106497B (en) | A kind of Chinese medicine and preparation method thereof treated hyperuricemia and merge dyslipidemia | |
| CN105412815A (en) | Traditional Chinese medicine composition for treating hyperthyroidism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120808 Termination date: 20150708 |
|
| EXPY | Termination of patent right or utility model |